RAPID MICRO BIOSYSTEMS’ GROWTH DIRECT PLATFORM CHOSEN TO REVOLUTIONISE BIOMANUFACTURING QUALITY CONTROL

KUALA LUMPUR, Jan 5 (Bernama) -- Rapid Micro Biosystems Inc announced that Samsung Biologics has selected its Growth Direct platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.

Rapid Micro Biosystems President and Chief Executive Officer, Robert Spignesi said: “The Growth Direct improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.

“Samsung Biologics is a leading global contract development and manufacturing organisation (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing.”

According to Rapid Micro Biosystems in a statement, global pharmaceutical manufacturers rely on the Growth Direct platform to meet both today’s microbiological quality control standards and tomorrow’s challenges.

It is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables.

-- BERNAMA